New! Sign up for our free email newsletter.
Science News
from research organizations

Early Treatment Of Macular Degeneration With Macugen May Help Patients Preserve Their Vision

Date:
October 7, 2005
Source:
University of California - Los Angeles
Summary:
The study found that early detection and treatment of age-related macular degeneration with pegaptanib sodium may enable AMD patients to maintain and, in some cases, regain vision.
Share:
FULL STORY

Age-related macular degeneration (AMD) is the leading cause ofblindness in older patients in the developed world. Vascularendothelial growth factor is one of the key mediators stimulating theabnormal blood vessel growth and leakage characteristic of theexudative (wet) form of the condition. Pegaptanib sodium (Macugen) is anew treatment for exudative AMD, and has been shown to stabilize visionin approximately 70 percent of cases.

The researchers performed an exploratory analysis of theoutcomes of patients with early exudative lesions at week 54 inclinical trials of pegaptanib sodium in the landmark VISION (VEGFInhibition Study in Ocular Neovascularization) study. The patients weredivided into two groups. The researchers found that at week 54, 76percent of patients in group 1 receiving pegaptanib lost fewer than 15letters or three lines of vision on the ETDRS eye chart, compared with50 percent of patients undergoing usual care. In group 2, thatproportion was 80 percent and 57 percent, respectively. A number ofpatients treated with pegaptanib even regained some sight. In addition,patients who underwent usual care for AMD were 10 times more likely toexperience severe vision loss than those treated with pegaptanib.

The study found that early detection and treatment ofage-related macular degeneration with pegaptanib sodium may enable AMDpatients to maintain and, in some cases, regain vision. As a result,the Jules Stein Eye Institute is launching a prospective, open-label,multi-center trial to evaluate the efficacy and safety of pegaptanib in40 patients with early onset of AMD.

The lead author is Dr. Christine R. Gonzales, assistant professor of ophthalmology at the Jules Stein Eye Institute at UCLA.

The research appears in the October 2005 issue of RETINA.

###

FUNDERS: Eyetech Pharmaceuticals Inc. and Pfizer Inc.


Story Source:

Materials provided by University of California - Los Angeles. Note: Content may be edited for style and length.


Cite This Page:

University of California - Los Angeles. "Early Treatment Of Macular Degeneration With Macugen May Help Patients Preserve Their Vision." ScienceDaily. ScienceDaily, 7 October 2005. <www.sciencedaily.com/releases/2005/10/051007084806.htm>.
University of California - Los Angeles. (2005, October 7). Early Treatment Of Macular Degeneration With Macugen May Help Patients Preserve Their Vision. ScienceDaily. Retrieved April 16, 2024 from www.sciencedaily.com/releases/2005/10/051007084806.htm
University of California - Los Angeles. "Early Treatment Of Macular Degeneration With Macugen May Help Patients Preserve Their Vision." ScienceDaily. www.sciencedaily.com/releases/2005/10/051007084806.htm (accessed April 16, 2024).

Explore More

from ScienceDaily

RELATED STORIES